

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
4 July 2002 (04.07.2002)

PCT

(10) International Publication Number  
**WO 02/051838 A1**

(51) International Patent Classification<sup>7</sup>: **C07D 405/12**,  
413/12, 417/12, 267/14, 223/16, 243/14, 285/36, 401/12,  
A61K 31/55

[CH/CH]; Actelion Pharmaceuticals Ltd., Obertorweg 64,  
CH-4123 Allschwil (CH).

(21) International Application Number: PCT/EP01/15074

(74) Agent: **HOFMANN, Dieter**; StratAll, Therwilerstr. 87,  
CH-4153 Reinach (CH).

(22) International Filing Date:  
19 December 2001 (19.12.2001)

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,  
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,  
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG,  
SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ,  
VN, YU, ZA, ZM, ZW.

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
PCT/EP00/13289  
27 December 2000 (27.12.2000) EP

(84) Designated States (*regional*): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),  
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR,  
GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent  
(BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,  
NE, SN, TD, TG).

(71) Applicant (*for all designated States except US*):  
**ACTELION PHARMACEUTICALS LTD.** [CH/CH];  
Gewerbstrasse 16, CH-4123 Allschwil (CH).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **AISSAOUI, Hamed**  
[FR/FR]; 01, Rue du Vieil Armand, F-68270 Witten-  
heim (FR). **CLOZEL, Martine** [FR/CH]; Winterhalde  
3b, CH-4102 Binningen (CH). **WELLER, Thomas**  
[CH/CH]; Hoelzlistrasse 58, CH-4102 Binningen (CH).  
**KOBERSTEIN, Ralf** [DE/DE]; Bergstrasse 34 b, 79539  
Lörrach (DE). **SIFFERLEN, Thierry** [FR/FR]; 6, rue de  
Thann, F-68116 Guewenheim (FR). **FISCHLI, Walter**

Published:

- with international search report
- before the expiration of the time limit for amending the  
claims and to be republished in the event of receipt of  
amendments

For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette:

(54) Title: NOVEL BENZAZEPINES AND RELATED HETEROCYCLIC DERIVATIVES WHICH ARE USEFUL AS OREXIN  
RECEPTOR ANTAGONISTS

(57) Abstract: The invention relates to novel benzazepines and related heterocyclic derivatives (I) and their use as active ingredients  
in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the prepara-  
tion of the compounds, pharmaceutical compositions containing one or more of those compounds and especially their use as orexin  
receptor antagonists.



**WO 02/051838 A1**

## NOVEL BENZAZEPINES AND RELATED HETEROCYCLIC DERIVATIVES WHICH ARE USEFUL AS OREXIN RECEPTOR ANTAGONISTS

5           The present invention relates to novel benzazepines and related heterocyclic derivatives of the general formula (I) and their use as pharmaceuticals. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more compounds of formula (I), and especially their use as orexin receptor antagonists.

10       The orexins (hypocretins) comprise two neuropeptides produced in the hypothalamus: the orexin A (OX-A) (a 33 aminoacid peptide) and the orexin B (OX-B) (a 28 aminoacid peptide). Orexins are found to stimulate food consumption in rats suggesting a physiological role for these peptides as mediators in the central feedback mechanism that regulates feeding behavior (Sakurai T. *et al.*, *Cell* 1998, 92, 573-585). On the other

15       hand, it was also proposed that orexins regulate states of sleep and wakefulness opening potentially novel therapeutic approaches for narcoleptic patients (Chemelli R.M. *et al.*, *Cell* 1999, 98, 437-451). Two orexin receptors have been cloned and characterized in mammals. They belong to the superfamily of G-protein coupled receptor (Sakurai T. *et al.*, *Cell* 1998, 92, 573-585). The orexin-1 receptor (OX<sub>1</sub>) is selective for OX-A and the

20       orexin-2 receptor (OX<sub>2</sub>) is capable to bind OX-A as well as OX-B.

          Orexin receptors are found in the mammalian host and may be responsible for many biological functions such as pathologies including, but not limited to, depression; anxiety; addictions; obsessive compulsive disorder; affective neurosis; depressive neurosis; anxiety neurosis; dysthymic disorder; behaviour disorder; mood disorder;

25       sexual dysfunction; psychosexual dysfunction; sex disorder; schizophrenia; manic depression; delirium; dementia; severe mental retardation and dyskinesias such as Huntington's disease and Tourette syndrome; eating disorders such as anorexia, bulimia, cachexia and obesity; diabetes; appetite/taste disorders; vomiting/nausea; asthma; cancer; Parkinson's disease; Cushing's syndrome/disease; basophil adenoma;

30       prolactinoma; hyperprolactinemia; hypopituitarism; hypophysis tumor/adenoma; hypothalamic diseases; inflammatory bowel disease; gastric dyskinesia; gastric ulcer; Froehlich's syndrome; adrenohypophysis disease; hypophysis disease; pituitary growth


hormone; adrenohypophysis hypofunction; adrenohypophysis hyperfunction; hypothalamic hypogonadism; Kallman's syndrome (anosmia, hyposmia); functional or psychogenic amenorrhea; hypopituitarism; hypothalamic hypothyroidism; hypothalamic-adrenal dysfunction; idiopathic hyperprolactinemia; hypothalamic disorders of growth hormone deficiency; idiopathic growth deficiency; dwarfism; gigantism; acromegaly; disturbed biological and circadian rhythms; sleep disturbances associated with diseases such as neurological disorders, neuropathic pain and restless leg syndrome; heart and lung diseases, acute and congestive heart failure; hypotension; hypertension; urinary retention; osteoporosis; angina pectoris; myocardial infarction; ischaemic or haemorrhagic stroke; subarachnoid haemorrhage; ulcers; allergies; benign prostatic hypertrophy; chronic renal failure; renal disease; impaired glucose tolerance; migraine; hyperalgesia; pain; enhanced or exaggerated sensitivity to pain such as hyperalgesia, causalgia, and allodynia; acute pain; burn pain; atypical facial pain; neuropathic pain; back pain; complex regional pain syndrome I and II; arthritic pain; sports injury pain; pain related to infection e.g. HIV, post-chemotherapy pain; post-stroke pain; post-operative pain; neuralgia; conditions associated with visceral pain such as irritable bowel syndrome, migraine and angina; urinary bladder incontinence e.g. urge incontinence; tolerance to narcotics or withdrawal from narcotics; sleep disorders; sleep apnea; narcolepsy; insomnia; parasomnia; jet-lag syndrome; and neurodegenerative disorders including nosological entities such as disinhibition-dementia-parkinsonism-amyotrophy complex; pallido-ponto-nigral degeneration epilepsy; seizure disorders and other diseases related to orexin.

The present invention provides benzazepines and related heterocyclic derivatives which are non-peptide antagonists of human orexin receptors, in particular  $OX_1$  and  $OX_2$  receptors. In particular, these compounds are of potential use in the treatment of obesity and/or sleep disorders.

So far not much is known about low molecular weight compounds which have a potential to antagonise either specifically  $OX_1$  or  $OX_2$  or both receptors at the same time. Recently WO 99/09024, WO 99/58533, WO 00/47577 and WO 00/47580 have been published wherein phenyl urea and phenyl thiourea derivatives are described as being preferably  $OX_1$  receptor antagonists. Also quite recently WO 00/47576 described

cinnamide derivatives as  $OX_1$  receptor antagonists. The novel compounds of the present invention belong to an entirely different class of low molecular weight compounds as compared to all prior art orexin receptor antagonists so far published.

5           The present invention relates to novel benzazepines and related heterocyclic derivatives of the general formula (I).



10

General formula (I)

wherein:

15

- $R^1$ ,  $R^2$ ,  $R^3$ ,  $R^4$  independently represent cyano, nitro, halogen, hydrogen, hydroxy, lower alkyl, lower alkenyl, lower alkoxy, lower alkenyloxy, trifluoromethyl, trifluoromethoxy, cycloalkyloxy, aryloxy, aralkyloxy, heterocyclyloxy, heterocyclylalkyloxy,  $R^{11}CO-$ ,  $NR^{12}R^{13}CO-$ ,  $R^{12}R^{13}N-$ ,  $R^{11}OOC-$ ,  $R^{11}SO_2NH-$ , or  $R^{14}-CO-NH-$ , or  $R^2$  and  $R^3$  together as well as  $R^1$  and  $R^2$  together and  $R^3$  and  $R^4$  together may form with the phenyl ring a five, six or seven-membered saturated ring containing one or two oxygen atoms;
- $R^5$  represents aryl, aralkyl, lower alkyl, lower alkenyl, trifluoromethyl, cycloalkyl, heterocyclyl or heterocyclyl-lower alkyl;
- 25    $R^6$  represents hydrogen, aryl, aralkyl, lower alkyl, lower alkenyl, trifluoromethyl, cycloalkyl, heterocyclyl or heterocyclyl-lower alkyl;
- $R^7$ ,  $R^8$  independently represent hydrogen, aryl, aralkyl, lower alkyl, lower alkenyl, cycloalkyl, heterocyclyl or heterocyclyl-lower alkyl;

$R^9$ ,  $R^{10}$  independently represent hydrogen, aryl, arylcycloalkyl, aralkyl, lower alkyl, lower alkenyl, lower alkynyl, cycloalkyl, heterocyclyl or heterocyclyl-lower alkyl, in which substituents one, several, or all hydrogen atoms may be replaced by halogen or in which one or two hydrogen atoms may be replaced by hydroxy, nitro, cyano, trifluoromethyl, trifluoromethoxy, -O-lower alkyl, -NH-lower alkyl, -N(lower alkyl)<sub>2</sub>, -S-lower alkyl, -COO-lower alkyl, -CONH-lower alkyl, -CON(lower alkyl)<sub>2</sub>, -CO-lower alkyl, -NCO-lower alkyl, -O-lower alkenyl with 3 to 5 carbon atoms, -NH-lower alkenyl with 3 to 5 carbon atoms, -N(lower alkenyl with 3 to 5 carbon atoms)<sub>2</sub>, -S-lower alkenyl with 3 to 5 carbon atoms, -COO-lower alkenyl with 3 to 5 carbon atoms, -CONH-lower alkenyl with 3 to 5 carbon atoms, -CON(lower alkenyl with 3 to 5 carbon atoms)<sub>2</sub>, -CO-lower alkenyl with 3 to 5 carbon atoms, -NHCO-lower alkenyl with 3 to 5 carbon atoms, -O-lower alkynyl with 3 to 5 carbon atoms, -NH-lower alkynyl with 3 to 5 carbon atoms, -N(lower alkynyl with 3 to 5 carbon atoms)<sub>2</sub>, -S-lower alkynyl with 3 to 5 carbon atoms, -COO-lower alkynyl with 3 to 5 carbon atoms, -CONH-lower alkynyl with 3 to 5 carbon atoms, -CON(lower alkynyl with 3 to 5 carbon atoms)<sub>2</sub>, -CO-lower alkynyl with 3 to 5 carbon atoms, -NHCO-lower alkynyl with 3 to 5 carbon atoms;  $R^{11}$  represents lower alkyl, aryl, aralkyl, heterocyclyl or heterocyclyl-lower alkyl;  $R^{12}$  and  $R^{13}$  independently represent hydrogen, lower alkyl, cycloalkyl, aryl, aralkyl, heterocyclyl or heterocyclyl-lower alkyl;  $R^{14}$  represents lower alkyl, aryl, cycloalkyl, heterocyclyl,  $R^{12}R^{13}N$ -,  $R^{11}O$ -, -X-Y- independently represents -CH<sub>2</sub>-CH<sub>2</sub>-, -O-CH<sub>2</sub>-, -S-CH<sub>2</sub>-, -SO<sub>2</sub>-CH<sub>2</sub>- and -NR<sup>15</sup>-CO-;  $R^{15}$  represents hydrogen, lower alkyl or aralkyl; and optically pure enantiomers, mixtures of enantiomers such as, for example, racemates, optically pure diastereoisomers, mixtures of diastereoisomers, diastereoisomeric racemates, mixtures of diastereoisomeric racemates, or meso forms and pharmaceutically acceptable salts thereof.

In the present description the term "lower alkyl", alone or in combination, signifies a straight-chain or branched-chain alkyl group with 1 to 8 carbon atoms, preferably a straight or branched-chain alkyl group with 1-4 carbon atoms. Examples of

straight-chain and branched C<sub>1</sub>-C<sub>8</sub> alkyl groups are methyl, ethyl, n-propyl, isopropyl, n-butyl, n-pentyl, n-hexyl, n-heptyl, n-octyl, isobutyl, tert-butyl, the isomeric pentyls, the isomeric hexyls, the isomeric heptyls and the isomeric octyls, preferably methyl, ethyl, n-propyl, isopropyl, n-butyl, 2-butyl, and *tert*-butyl.

5

The term "lower alkenyl", alone or in combination, if not otherwise defined signifies a straight-chain or branched-chain alkenyl group with 2 to 5 carbon atoms, preferably allyl and vinyl.

10       The term "lower alkynyl", alone or in combination, signifies a straight-chain or branched-chain alkynyl group with 2 to 5 carbon atoms, preferably propargyl and n-butynyl.

15       The term "lower alkoxy", alone or in combination, signifies a group of the formula lower alkyl-O- in which the term "lower alkyl" has the previously given significance, such as methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy and tert-butoxy, preferably methoxy and ethoxy.

Lower alkenyloxy groups are preferably vinyloxy and allyloxy.

20

The term "cycloalkyl", alone or in combination, signifies a cycloalkyl ring with 3 to 8 carbon atoms and preferably a cycloalkyl ring with 3 to 6 carbon atoms.

Examples of C<sub>3</sub>-C<sub>8</sub> cycloalkyl groups are cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl, preferably cyclopropyl, cyclopentyl, 25 cyclohexyl and particularly cyclohexyl or lower alkyl substituted cycloalkyl which may preferably be substituted with lower alkyl, such as methyl-cyclopropyl, dimethyl-cyclopropyl, methyl-cyclobutyl, methyl-cyclopentyl, methyl-cyclohexyl, dimethyl-cyclohexyl.

30       The term "aryl", alone or in combination, signifies a phenyl or naphthyl group which optionally carries one or more substituents, preferably one or two substituents,

each independently selected from cyano, halogen, hydroxy, lower alkyl, lower alkenyl, lower alkoxy, lower alkenyloxy, nitro, trifluoromethyl, trifluoromethoxy, amino, carboxy and the like, such as phenyl, p-tolyl, 4-methoxyphenyl, 4-tert-butoxyphenyl, 4-fluorophenyl, 2-chlorophenyl, 4-hydroxyphenyl, 1-naphthyl and 2-naphthyl. Preferred  
5 are carboxyphenyl, lower alkoxy-phenyl, hydroxyphenyl and particularly phenyl.

The term "aralkyl", alone or in combination, signifies a lower alkyl or cycloalkyl group as previously defined in which one hydrogen atom has been replaced by an aryl group as previously defined. Preferred are benzyl and benzyl substituted in  
10 the phenyl ring with hydroxy, lower alkyl, lower alkoxy or halogen preferably chlorine. Particularly preferred is benzyl.

The term "arylcycloalkyl", alone or in combination, signifies an arylcycloalkyl group wherein the cycloalkyl moiety consists of 4 to 7 carbon atoms e.g. indanyl, tetrahydronaphthyl, benzocycloheptyl and benzocyclobutyl. The aromatic moiety may  
15 be substituted with one or more substituents, preferably one or two substituents, each independently selected from cyano, halogen, hydroxy, lower alkyl, lower alkenyl, lower alkoxy, lower alkenyloxy, nitro, trifluoromethyl, trifluoromethoxy, amino and carboxy.


For the term "heterocyclyl" and "heterocyclyl-lower alkyl", the heterocyclyl group is preferably a 5- to 10-membered monocyclic or bicyclic ring, which may be saturated, partially unsaturated or aromatic containing for example 1, 2 or 3 heteroatoms selected from oxygen, nitrogen and sulphur which may be the same or different. Example of such heterocyclyl groups are pyrrolidinyl, piperidinyl,  
20 piperazinyl, morpholinyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, quinolyl, isoquinolyl, thienyl, thiazolyl, isothiazolyl, furyl, imidazolyl, pyrazolyl, pyrrolyl, indazolyl, indolyl, isoindolyl, isoxazolyl, oxazolyl, quinoxalinyl, phthalazinyl, cinnolinyl, dihydropyrrolyl, isobenzofuranyl, tetrahydrofuranlyl, dihydropyranyl. The heterocyclyl group may have up to 5, preferably 1, 2 or 3 optional substituents.  
25 Examples of suitable substituents include halogen, lower alkyl, amino, nitro, cyano, hydroxy, lower alkoxy, carboxy and lower alkyloxy-carbonyls.

The term "halogen" signifies fluorine, chlorine, bromine or iodine and preferably fluorine and chlorine.

The term "carboxy", alone or in combination, signifies a  $\text{-COOH}$  group.

5

A group of preferred compounds according to the present invention are compounds of formula (II)



10

Formula (II)

15 wherein:

$R^1, R^2, R^3, R^4$  independently represent cyano, nitro, halogen, hydrogen, hydroxy, lower alkyl, lower alkenyl, lower alkoxy, lower alkenyloxy, trifluoromethyl, trifluoromethoxy, cycloalkyloxy, aryloxy, aralkyloxy, heterocyclyloxy, heterocyclylalkyloxy,  $R^{11}\text{CO-}$ ,  $\text{NR}^{12}\text{R}^{13}\text{CO-}$ ,  $\text{R}^{12}\text{R}^{13}\text{N-}$ ,  $\text{R}^{11}\text{OOC-}$ ,  $\text{R}^{11}\text{SO}_2\text{NH-}$ , or  $\text{R}^{14}\text{CO-NH-}$ , or  $R^2$  and  $R^3$  together as well as  $R^1$  and  $R^2$  together and  $R^3$  and  $R^4$  together may form with the phenyl ring a five, six or seven-membered saturated ring containing one or two oxygen atoms;

$R^5$  represents aryl, aralkyl, lower alkyl, lower alkenyl, trifluoromethyl, cycloalkyl, heterocyclyl or heterocyclyl-lower alkyl;

$R^6$  represents hydrogen, aryl, aralkyl, lower alkyl, lower alkenyl, trifluoromethyl, cycloalkyl, heterocyclyl or heterocyclyl-lower alkyl;

$R^7, R^8, R^9, R^{10}$  independently represent hydrogen, aryl, aralkyl, lower alkyl, lower alkenyl, cycloalkyl, heterocyclyl or heterocyclyl-lower alkyl;

$R^{11}$  represents lower alkyl, aryl, aralkyl, heterocyclyl or heterocyclyl-lower alkyl;

30



$R^{12}$  and  $R^{13}$  independently represent hydrogen, lower alkyl, cycloalkyl, aryl, aralkyl, heterocyclyl or heterocyclyl-lower alkyl;


$R^{14}$  represents lower alkyl, aryl, cycloalkyl, heterocyclyl,  $R^{12}R^{13}N$ -,  $R^{11}O$ -;

-X-Y- independently represents  $-CH_2-CH_2-$ ,  $-O-CH_2-$ ,  $-S-CH_2-$ ,  $-SO_2-CH_2-$  and  $-NR^{15}-CO$ -;

$R^{15}$  represents hydrogen, lower alkyl or aralkyl;

and optically pure enantiomers, mixtures of enantiomers such as, for example, racemates, optically pure diastereoisomers, mixtures of diastereoisomers, diastereoisomeric racemates, mixtures of diastereoisomeric racemates, or meso forms and pharmaceutically acceptable salts thereof.

Another group of preferred compounds according to the present invention are compounds of formula (III)



Formula (III)

wherein:

$R'^1$  and  $R'^2$  independently represent hydrogen, hydroxy, lower alkoxy, lower alkenyloxy or halogen or may form with the phenyl ring a five, six or seven membered-ring containing one or two oxygen atoms;

$R'^3$  represents aryl, aralkyl, lower alkyl, lower alkenyl, cycloalkyl, heterocyclyl or heterocyclyl-lower alkyl;

$R'^4$ ,  $R'^5$  independently represent hydrogen, aryl, aralkyl, lower alkyl, lower alkenyl, cycloalkyl, heterocyclyl or heterocyclyl-lower alkyl;

-X-Y- independently represents  $-CH_2-CH_2-$ ,  $-O-CH_2-$ ,  $-S-CH_2-$ ,  $-SO_2-CH_2-$  and  $-NR'^6-CO$ -;

R<sup>6</sup> represents hydrogen, lower alkyl or aralkyl;  
and optically pure enantiomers, mixtures of enantiomers such as, for example,  
racemates, optically pure diastereoisomers, mixtures of diastereoisomers,  
diastereoisomeric racemates, mixture of diastereoisomeric racemates, or meso forms  
5 and pharmaceutically acceptable salts thereof.

Examples of preferred compounds are:

2-[1-(3,4-Dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-  
10 *N*-naphthalen-1-ylmethyl-acetamide

*N*-Benzo[1,3]dioxol-5-ylmethyl-2-[1-(3,4-dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-  
tetrahydro-benzo[c]azepin-2-yl]-acetamide

15 2-[1-(3,4-Dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-  
*N*-indan-2-yl-acetamide

2-[5-(3,4-Dimethoxy-benzyl)-7,8-dimethoxy-2,3-dihydro-5H-benzo[f][1,4]oxazepin-4-  
yl]-*N*-indan-2-yl-acetamide

20 2-[5-(3,4-Dimethoxy-benzyl)-7,8-dimethoxy-2,3-dihydro-5H-benzo[f][1,4]oxazepin-4-  
yl]-*N*-indan-1-yl-acetamide

2-[1-(3,4-Dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-  
25 *N*-indan-1-yl-acetamide

2-[9-(3,4-Dimethoxy-benzyl)-2,3-dimethoxy-5,5-dioxo-5,6,7,9-tetrahydro-5λ-thia-8-  
aza-benzocyclohepten-8-yl]-*N*-indan-2-yl-acetamide

30 2-[9-(3,4-Dimethoxy-benzyl)-2,3-dimethoxy-5,5-dioxo-5,6,7,9-tetrahydro-5λ-thia-8-  
aza-benzocyclohepten-8-yl]-*N*-indan-1-yl-acetamide

- 2-[1-(3,4-Dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-  
*N*-indan-1-yl-acetamide
- 2-[1-(3,4-Dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-  
5 *N*-indan-2-yl-2-phenyl-acetamide
- 2-[9-(3,4-Dimethoxy-benzyl)-2,3-dimethoxy-6,7-dihydro-9H-5-thia-8-aza-  
benzocyclohepten-8-yl]-*N*-naphthalen-1-ylmethyl-acetamide
- 10 2-[9-(3,4-Dimethoxy-benzyl)-2,3-dimethoxy-6,7-dihydro-9H-5-thia-8-aza-  
benzocyclohepten-8-yl]-*N*-(2-ethoxy-benzyl)-acetamide
- 2-[9-(3,4-Dimethoxy-benzyl)-2,3-dimethoxy-6,7-dihydro-9H-5-thia-8-aza-  
benzocyclohepten-8-yl]-*N*-indan-1-yl-acetamide
- 15 2-[5-(3,4-Dimethoxy-benzyl)-7,8-dimethoxy-2,3-dihydro-5H-benzo[f][1,4]oxazepin-4-  
yl]-*N*-(1,2,3,4-tetrahydro-naphthalen-1-yl)-acetamide
- N*-Benzyl-2-[9-(3,4-dimethoxy-benzyl)-2,3-dimethoxy-6,7-dihydro-9H-5-thia-8-aza-  
20 benzocyclohepten-8-yl]-acetamide
- 2-[5-(3,4-Dimethoxy-benzyl)-7,8-dimethoxy-2,3-dihydro-5H-benzo[f][1,4]oxazepin-4-  
yl]-*N*-indan-1-yl-acetamide
- 25 *N*-Butyl-2-[1-(3,4-dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-  
benzo[c]azepin-2-yl]-2-phenyl-acetamide
- 2-[1-(3,4-Dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-  
*N*-indan-1-yl-2-phenyl-acetamide

*N*-Benzo[1,3]dioxol-5-ylmethyl-2-[1-(3,4-dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-2-phenyl-acetamide

5 *N*-Cyclopentyl-2-[1-(3,4-dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-2-phenyl-acetamide

2-[1-(3,4-Dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-*N*-furan-2-ylmethyl-2-phenyl-acetamide

10 {2-[1-(3,4-Dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-2-phenyl-acetylamino}-acetic acid ethyl ester

2-[1-(3,4-Dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-2-phenyl-*N*-pyridin-4-ylmethyl-acetamide

15 2-[1-(3,4-Dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-2-phenyl-*N*-pyridin-3-ylmethyl-acetamide

*N*-Cyclopropyl-2-[1-(3,4-dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-2-phenyl-acetamide

20 2-[1-(3,4-Dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-*N*-(2-oxo-tetrahydro-furan-3-yl)-2-phenyl-acetamide

25 2-[1-(3,4-Dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-*N*-(4-methoxy-indan-1-yl)-acetamide

2-[1-(3,4-Dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-*N*-(3-phenyl-indan-1-yl)-acetamide

30

2-[1-(3,4-Dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-  
*N*-(4-methyl-indan-1-yl)-acetamide

2-{2-[1-(3,4-Dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-  
5 yl]-2-phenyl-acetyl-amino}-3-hydroxy-propionic acid methyl ester

2-[1-(3,4-Dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-  
*N*-ethylcarbamoylmethyl-2-phenyl-acetamide

10 2-[1-(3,4-Dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-  
*N*-[(ethyl-methyl-carbamoyl)-methyl]-2-phenyl-acetamide

2-[1-(3,4-Dimethoxy-benzyl)-8-hydroxy-7-methoxy-1,3,4,5-tetrahydro-benzo[c]azepin-  
2-yl]-*N*-indan-1-yl-acetamide

15

2-[8-Benzoyloxy-1-(3,4-dimethoxy-benzyl)-7-methoxy-1,3,4,5-tetrahydro-  
benzo[c]azepin-2-yl]-*N*-indan-1-yl-acetamide

3-{2-[1-(3,4-Dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-  
20 yl]-2-phenyl-acetyl-amino}-propionic acid methyl ester

*N*-Benzo[1,3]dioxol-5-ylmethyl-2-[1-(3,4-dimethoxy-benzyl)-8-hydroxy-7-methoxy-  
1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-2-phenyl-acetamide

25 *N*-(1*H*-Benzoimidazol-2-ylmethyl)-2-[1-(3,4-dimethoxy-benzyl)-7,8-dimethoxy-  
1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-2-phenyl-acetamide

3-{2-[1-(3,4-Dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-  
yl]-2-phenyl-acetyl-amino}-*N,N*-dimethyl-propionamide

30

3-{2-[1-(3,4-Dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-2-phenyl-acetylamino}-*N*-ethyl-*N*-methyl-propionamide

2-[1-(3,4-Dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-  
5 *N*-(1-methyl-1H-indol-3-ylmethyl)-2-phenyl-acetamide

2-[1-(3,4-Dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-  
*N*-isoxazol-5-ylmethyl-2-phenyl-acetamide

10 2-[1-(3,4-Dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-  
*N*-(1H-indol-3-ylmethyl)-2-phenyl-acetamide

2-[1-(3,4-Dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-  
*N*-(1-methyl-1H-benzimidazol-2-ylmethyl)-2-phenyl-acetamide  
15

2-[1-(3,4-Dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-  
*N*-isoquinolin-1-ylmethyl-2-phenyl-acetamide

2-[1-(3,4-Dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-  
20 2-phenyl-*N*-(4-[1,2,3]thiadiazol-4-yl-benzyl)-acetamide

2-[1-(3,4-Dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-  
*N*-(1-methyl-1H-indazol-3-ylmethyl)-2-phenyl-acetamide

25 *N*-Cyanomethyl-2-[1-(3,4-dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-  
benzo[c]azepin-2-yl]-2-phenyl-acetamide

*N*-(2-Acetylamino-ethyl)-2-[1-(3,4-dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-  
tetrahydro-benzo[c]azepin-2-yl]-2-phenyl-acetamide

2-[1-(3,4-Dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-  
2-phenyl-*N*-(2,2,2-trifluoro-ethyl)-acetamide

2-[1-(3,4-Dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-  
5 *N*-(2-methylsulfanyl-ethyl)-2-phenyl-acetamide

2-[1-(3,4-Dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-  
2-phenyl-*N*-quinolin-2-ylmethyl-acetamide

10 *N*-(2-Cyano-ethyl)-2-[1-(3,4-dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-  
benzo[c]azepin-2-yl]-2-phenyl-acetamide

2-[1-(3,4-Dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-  
*N*-(3-methoxy-propyl)-2-phenyl-acetamide

15 2-[1-(3,4-Dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-  
*N*-(3-ethoxy-propyl)-2-phenyl-acetamide

2-[1-(3,4-Dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-  
20 2-phenyl-acetamide

2-[1-(3,4-Dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-  
2-phenyl-*N*-pyrazin-2-ylmethyl-acetamide

25 2-[1-(3,4-Dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-  
2-phenyl-*N*-prop-2-ynyl-acetamide

*N*-tert-Butyl-2-[1-(3,4-dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-  
benzo[c]azepin-2-yl]-2-phenyl-acetamide

30

2-[1-(3,4-Dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-  
*N*-(3-methyl-butyl)-2-phenyl-acetamide

2-[1-(3,4-Dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-  
5 *N*-(3,3-dimethyl-butyl)-2-phenyl-acetamide

2-[1-(3,4-Dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-  
*N*-(1-ethyl-propyl)-2-phenyl-acetamide

10 2-[1-(3,4-Dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-  
*N*-(2-ethylsulfanyl-ethyl)-2-phenyl-acetamide

2-[1-(3,4-Dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-  
*N*-(2-hydroxy-ethyl)-2-phenyl-acetamide

15 2-[1-(3,4-Dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-  
*N*-(3-hydroxy-propyl)-2-phenyl-acetamide

[1-(3,4-Dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-  
20 phenyl-acetic acid *N,N'*-dimethyl-hydrazide

2-[8-Allyloxy-1-(3,4-dimethoxy-benzyl)-7-methoxy-1,3,4,5-tetrahydro-benzo[c]azepin-  
2-yl]-*N*-indan-1-yl-acetamide

25 2-[1-(3,4-Dimethoxy-benzyl)-7-methoxy-8-propoxy-1,3,4,5-tetrahydro-benzo[c]azepin-  
2-yl]-*N*-indan-1-yl-acetamide

2-[1-(3,4-Dimethoxy-benzyl)-8-isopropoxy-7-methoxy-1,3,4,5-tetrahydro-  
benzo[c]azepin-2-yl]-*N*-indan-1-yl-acetamide

30



2-[8-(2,2-Difluoro-ethoxy)-1-(3,4-dimethoxy-benzyl)-7-methoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-*N*-indan-1-yl-acetamide

*N*-Benzo[1,3]dioxol-5-ylmethyl-2-[8-(2,2-difluoro-ethoxy)-1-(3,4-dimethoxy-benzyl)-7-methoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-2-phenyl-acetamide

*N*-Benzo[1,3]dioxol-5-ylmethyl-2-[1-(3,4-dimethoxy-benzyl)-8-isopropoxy-7-methoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-2-phenyl-acetamide

2-[5-(3,4-Dichloro-benzyl)-7,8-dimethoxy-2-oxo-1,2,3,5-tetrahydro-benzo[e][1,4]diazepin-4-yl]-*N*-indan-1-yl-acetamide

2-[1-(*S*)-(3,4-Dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-*N*-indan-1-yl-acetamide

2-[1-(*S*)-(3,4-Dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-*N*-indan-2-yl-acetamide

Examples of particularly preferred compounds are:

2-[1-(3,4-Dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-*N*-indan-2-yl-acetamide

2-[5-(3,4-Dimethoxy-benzyl)-7,8-dimethoxy-2,3-dihydro-5H-benzo[f][1,4]oxazepin-4-yl]-*N*-indan-1-yl-acetamide

2-[1-(3,4-Dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-*N*-indan-1-yl-acetamide

2-[1-(3,4-Dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-*N*-indan-1-yl-acetamide

2-[1-(3,4-Dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-*N*-indan-2-yl-2-phenyl-acetamide

*N*-Butyl-2-[1-(3,4-dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-2-phenyl-acetamide

- 5     2-[1-(3,4-Dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-  
*N*-indan-1-yl-2-phenyl-acetamide

*N*-Benzo[1,3]dioxol-5-ylmethyl-2-[1-(3,4-dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-2-phenyl-acetamide

10

*N*-Cyclopentyl-2-[1-(3,4-dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-2-phenyl-acetamide

- 2-[1-(3,4-Dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-  
15     *N*-furan-2-ylmethyl-2-phenyl-acetamide

{2-[1-(3,4-Dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-  
2-phenyl-acetylamino}-acetic acid ethyl ester

- 20     2-[1-(3,4-Dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-  
2-phenyl-*N*-pyridin-3-ylmethyl-acetamide

3-{2-[1-(3,4-Dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-  
2-phenyl-acetylamino}-propionic acid methyl ester

25

*N*-(1H-Benzoimidazol-2-ylmethyl)-2-[1-(3,4-dimethoxy-benzyl)-7,8-dimethoxy-  
1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-2-phenyl-acetamide

- 2-[1-(3,4-Dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-  
30     *N*-(1-methyl-1H-indol-3-ylmethyl)-2-phenyl-acetamide

2-[1-(3,4-Dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-  
*N*-isoxazol-5-ylmethyl-2-phenyl-acetamide

2-[1-(3,4-Dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-  
5 *N*-(1H-indol-3-ylmethyl)-2-phenyl-acetamide

2-[1-(3,4-Dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-  
*N*-isoquinolin-1-ylmethyl-2-phenyl-acetamide

10 2-[1-(3,4-Dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-  
2-phenyl-*N*-(4-[1,2,3]thiadiazol-4-yl-benzyl)-acetamide

2-[1-(3,4-Dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-  
*N*-(1-methyl-1H-indazol-3-ylmethyl)-2-phenyl-acetamide

15 *N*-Cyanomethyl-2-[1-(3,4-dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-  
benzo[c]azepin-2-yl]-2-phenyl-acetamide

2-[1-(3,4-Dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-  
20 2-phenyl-*N*-(2,2,2-trifluoro-ethyl)-acetamide

2-[1-(3,4-Dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-  
*N*-(2-methylsulfanyl-ethyl)-2-phenyl-acetamide

25 2-[1-(3,4-Dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-  
2-phenyl-*N*-quinolin-2-ylmethyl-acetamide

*N*-(2-Cyano-ethyl)-2-[1-(3,4-dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-  
benzo[c]azepin-2-yl]-2-phenyl-acetamide

2-[1-(3,4-Dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-  
*N*-(3-methoxy-propyl)-2-phenyl-acetamide

2-[1-(3,4-Dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-  
5 *N*-(3-ethoxy-propyl)-2-phenyl-acetamide

2-[1-(3,4-Dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-  
2-phenyl-*N*-pyrazin-2-ylmethyl-acetamide

10 2-[1-(3,4-Dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-  
2-phenyl-*N*-prop-2-ynyl-acetamide

2-[1-(3,4-Dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-  
*N*-(3-methyl-butyl)-2-phenyl-acetamide

15 2-[1-(3,4-Dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-  
*N*-(3,3-dimethyl-butyl)-2-phenyl-acetamide

2-[1-(3,4-Dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-  
20 *N*-(1-ethyl-propyl)-2-phenyl-acetamide

2-[1-(3,4-Dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-  
*N*-(2-ethylsulfanyl-ethyl)-2-phenyl-acetamide

25 2-[1-(3,4-Dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-  
*N*-(2-hydroxy-ethyl)-2-phenyl-acetamide

2-[8-Allyloxy-1-(3,4-dimethoxy-benzyl)-7-methoxy-1,3,4,5-tetrahydro-benzo[c]azepin-  
2-yl]-*N*-indan-1-yl-acetamide

2-[1-(3,4-Dimethoxy-benzyl)-7-methoxy-8-propoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-*N*-indan-1-yl-acetamide

2-[1-(3,4-Dimethoxy-benzyl)-8-isopropoxy-7-methoxy-1,3,4,5-tetrahydro-  
5 benzo[c]azepin-2-yl]-*N*-indan-1-yl-acetamide

2-[8-(2,2-Difluoro-ethoxy)-1-(3,4-dimethoxy-benzyl)-7-methoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-*N*-indan-1-yl-acetamide

10 *N*-Benzo[1,3]dioxol-5-ylmethyl-2-[8-(2,2-difluoro-ethoxy)-1-(3,4-dimethoxy-benzyl)-7-methoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-2-phenyl-acetamide

*N*-Benzo[1,3]dioxol-5-ylmethyl-2-[1-(3,4-dimethoxy-benzyl)-8-isopropoxy-7-methoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-2-phenyl-acetamide

15 2-[1-(*S*)-(3,4-Dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-*N*-indan-1-yl-acetamide

20 2-[1-(*S*)-(3,4-Dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-*N*-indan-2-yl-acetamide

Examples of physiologically usable or pharmaceutically acceptable salts of the compounds of general formula (I) are salts with physiologically compatible mineral acids such as hydrochloric acid, sulfuric or phosphoric acid, or with organic acids such as methanesulphonic acid, acetic acid, trifluoroacetic acid, citric acid, fumaric acid, maleic acid, tartaric acid, succinic acid or salicylic acid. Compounds of formula (I) with acidic groups can also form salts with physiologically compatible bases. Examples of such salts are alkali metal, earth alkali metal, ammonium and alkylammonium salts such as Na, K, Ca or tetraalkylammonium salts. The compounds of general formula (I) can also be present in the form of a zwitterion.

Preferred compounds as described above have IC<sub>50</sub> values below 1000 nM; particularly preferred compounds have IC<sub>50</sub> values below 100 nM which have been

determined with the FLIPR (Fluorometric Imaging Plates Reader) method described in the beginning of the experimental section.

5 The compounds of the general formula (I) and their pharmaceutically usable salts can be used for the treatment of diseases or disorders where an antagonist of a human orexin receptor is required such as obesity, diabetes, cardiovascular disorders, cancer, prolactinoma, pain, narcolepsy, insomnia, sleep apnea, parasomnia, depression, anxiety, addictions, schizophrenia, neurodegenerative disorders and dementia.

10 The compounds of general formula (I) and their pharmaceutically usable salts are particularly useful for the treatment of obesity and sleep disorders.

The compounds of general formula (I) and their pharmaceutically usable salts can be used as medicament (e.g. in the form of pharmaceutical preparations). The pharmaceutical preparations can be administered in enteral or oral form (e.g. in the form of tablets, coated tablets, dragées, hard and soft gelatine capsules, solutions, emulsions or suspensions), nasally (e.g. in the form of nasal sprays) or rectally (e.g. in the form of suppositories). However, the administration can also be effected parenterally, such as intramuscularly or intravenously (e.g. in the form of injection solutions).

20 The compounds of general formula (I) and their pharmaceutically usable salts can be processed with pharmaceutically inert, inorganic or organic excipients for the production of tablets, coated tablets, dragées, and hard gelatine capsules. Lactose, corn starch or derivatives thereof, talc, stearic acid or its salts etc. can be used, for example, as such adjuvants for tablets, dragées, and hard gelatine capsules.

Suitable adjuvants for soft gelatine capsules, are, for example, vegetable oils, waxes, fats, semi-solid substances and liquid polyols, etc.

30

Suitable adjuvants for the production of solutions and syrups are, for example, water, polyols, saccharose, invert sugar, glucose, etc.

Suitable adjuvants for injection solutions are, for example, water, alcohols, polyols, glycerol, vegetable oils, etc.

5            Suitable adjuvants for suppositories are, for example, natural or hardened oils, waxes, fats, semi-solid or liquid polyols, etc.

Moreover, the pharmaceutical preparations can contain preservatives, solubilizers, viscosity-increasing substances, stabilizers, wetting agents, emulsifiers,  
10    sweeteners, colorants, flavorants, salts for varying the osmotic pressure, buffers, masking agents or antioxidants. They can also contain still other therapeutically valuable substances. The invention also relates to processes for the preparation of compounds of general formula (I).


15            The compounds of general formula (I) of the present invention are prepared according to the general sequence of reactions outlined in the schemes below, wherein  $R^1, R^2, R^3, R^4, R^5, R^6, R^7, R^8, R^9, R^{10}, R^{11}, R^{12}, R^{13}, R^{14}, R^{15}$  are as defined in general formula (I) above. As the case may be any compound obtained with one or more optically active carbon atom may be resolved into pure enantiomers or diastereomers,  
20    mixtures of enantiomers or diastereomers, diastereomeric racemates and the meso-forms in a manner known per se.

The compounds obtained may also be converted into a pharmaceutically acceptable salt thereof in a manner known per se.

25

The compounds of the general formula (I) may be prepared by standard procedures


(*Procedure A* wherein R<sup>7</sup> and R<sup>8</sup> are hydrogen atoms and *Procedure B* wherein R<sup>7</sup> and/or R<sup>8</sup> are other than hydrogen) shown in *Scheme 1* using synthesized benzazepine and related heterocyclic derivatives.



Scheme 1



Benzazepine derivatives wherein X and Y are CH<sub>2</sub> and R<sup>6</sup> is hydrogen might be prepared from the corresponding phenylpropylamine by coupling with the desired carboxylic acid or acyl chloride followed by treatment with POCl<sub>3</sub> and finally NaBH<sub>4</sub> (*Bischler-Napieralski* reaction) as shown in *Scheme 2a* (S. Kano *et al.*, *Chem. Pharm. Bull.* 1977, 25, 10, 2510-2515).




Scheme 2a

10

Benzazepines with variable substituents on position 8 might be prepared by hydrogenolysis of the corresponding 8-benzyloxy-1,3,4,5-tetrahydro-benzazepines followed by *O*-alkylation with the appropriate electrophile (*Scheme 2b*, -OR'<sub>11</sub> being included in the definition of R<sub>3</sub>). The benzyloethers can be obtained with the previous procedure (*Scheme 2a*) applied to 3-(4-benzyloxy-phenyl)-propionic acid derivatives.

20




5

Scheme 2b

Benzothiazepine and benzoxazepine derivatives wherein X is O or S, Y is  $\text{CH}_2$  and  $\text{R}^6$  is hydrogen might be prepared from the corresponding arylamine by coupling with the desired carboxylic acid or acyl chloride followed by treatment with  $\text{POCl}_3$  and finally  $\text{NaBH}_4$  (*Bischler-Napieralski reaction*) as shown in *Scheme 3*.

15



Scheme 3


10

1,3,4,5-Tetrahydro-2H-1,4-benzodiazepin-2-one derivatives wherein X is NR<sup>15</sup>, Y is CO and R<sup>6</sup> is hydrogen might be prepared by *Friedel-Crafts* acylation of the appropriate acetylated-aniline with the respective acyl chloride (Sternbach L.H. *et al.*, *J. Org. Chem.* 1962, 27, 3781-3788), followed by *N*-deprotection, cyclisation by treatment with methyl esters of  $\alpha$ -amino acids (Sternbach L.H. *et al.*, *J. Org. Chem.* 1962, 27, 3788-3796) and finally hydrogenolysis of the dihydro compound (Fryer R.I. *et al.*, *J. Med. Chem.* 1964, 386-389) (Scheme 4a). An alternative synthetic approach to such 1,3,4,5-tetrahydro-2H-1,4-benzodiazepin-2-one derivatives is described in Scheme 4b. According to this methodology, the arylketone derivative is obtained by *Friedel-Crafts* acylation and a subsequent nitration and hydrogenation led to the aniline derivative. The 1,3-dihydro-benzo[e][1,4]diazepin-2-one skeleton is then obtained according to a well-described cyclisation procedure involving bromoacetyl bromide and


20

ammonia (Bock M.G. *et al.*, *J. Org. Chem.* **1987**, 3232-3239; Zhang W. *et al.*, *J. Med. Chem.* **1994**, 745-757). At this stage the amide can be *N*-alkylated and the 1,3,4,5-tetrahydro-2*H*-1,4-benzodiazepin-2-one derivative was finally obtained by hydride reduction (Gilman N.W. *et al.*, *J. Am. Chem. Soc.* **1990**, 3969-3978).

5




Scheme 4a



Scheme 4b

For the preparation of benzazepine derivatives with electron-withdrawing substituents on the phenyl ring, the previous procedures based on the *Bischler-Napieralski* reaction are incompatible. Therefore cyano groups might be introduced by reaction of a triflate with cyanide ions in the presence of palladium(0) (Austin N.E. *et al.*, *Bioorg. Med. Chem. Lett.* **2000**, *10*, 2553-2555; Ritter K. *et al.*, *Synthesis* **1993**, 735; Selnick H.G. *et al.*, *Synth. Commun.* **1995**, *25*, 20, 3255-3262) (Scheme 5).


10



15

Scheme 5


Carboxylate groups might also be introduced by reaction of a triflate with carbon monoxide and an alcohol in the presence of palladium(0) (Roth G.P. *et al.*, *Tetrahedron Lett.* 1992, 33, 1959; Ma D. *et al.*, *Bioorg. Med. Chem. Lett.* 1998, 8, 18, 2447-2450; Fisher M.J. *et al.*, *J. Med. Chem.* 1997, 40, 2085-2101; Kraus G.A. *et al.*, *Tetrahedron Lett.* 1994, 35, 9189-9190). These carboxylate functions can subsequently be converted into amino functionalities by hydrolysis followed by Curtius reaction (Scheme 6).



10

Scheme 6

Halogen containing 2-benzazepines may be prepared by treatment of halogenated tetralone oximes with POCl<sub>3</sub>/DMF and the resulting 1,3,4,5-tetrahydro-1-oxo-2H-2-benzazepine-2-carboxaldehydes can be subsequently deformylated and reduced (Majo V.J. *et al.*, *Synth. Commun.* 1995, 25, 23, 3863-3868) (Scheme 7).




20

Scheme 7

5 8-nitro-2,3,4,5-tetrahydro-1*H*-2-benzazepine might be prepared by regioselective nitration of 2,3,4,5-tetrahydro-1*H*-2-benzazepin-1-one using potassium nitrate and sulfuric acid (Grunewald G.L. *et al.*, *J. Heterocyclic Chem.* 1994, 31, 1609-1617) (*Scheme 8*).

10




15

*Scheme 8*

20

The preparation of enantiomerically pure 1-substituted-2-tetrahydrobenzazepine derivatives (*Scheme 9*) was based on a methodology described for the synthesis of optically pure 1-substituted tetrahydroisoquinolines (Polniaszek R.P. *et al.*, *J. Am. Chem. Soc.* 1989, 111, 4859-4863). The key step of this asymmetric synthesis is a stereoselective hydride reduction of a chiral imminium ion obtained by *Bischler-Napieralski* reaction. The chirality resident in the substrate would be derived from the commercially available (*S*)-(-)- $\alpha$ -phenethylamine.

25




Scheme 9



## Claims

1. Compounds of the general formula (I)



General formula (I)

10

wherein:

- $R^1$ ,  $R^2$ ,  $R^3$ ,  $R^4$  independently represent cyano, nitro, halogen, hydrogen, hydroxy, lower alkyl, lower alkenyl, lower alkoxy, lower alkenyloxy, trifluoromethyl, trifluoromethoxy, cycloalkyloxy, aryloxy, aralkyloxy, heterocyclyloxy, heterocyclylalkyloxy,  $R^{11}CO-$ ,  $NR^{12}R^{13}CO-$ ,  $R^{12}R^{13}N-$ ,  $R^{11}OOC-$ ,  $R^{11}SO_2NH-$ , or  $R^{14}CO-NH-$ , or  $R^2$  and  $R^3$  together as well as  $R^1$  and  $R^2$  together and  $R^3$  and  $R^4$  together may form with the phenyl ring a five, six or seven-membered saturated ring containing one or two oxygen atoms;
- $R^5$  represents aryl, aralkyl, lower alkyl, lower alkenyl, trifluoromethyl, cycloalkyl, heterocyclyl or heterocyclyl-lower alkyl;
- $R^6$  represents hydrogen, aryl, aralkyl, lower alkyl, lower alkenyl, trifluoromethyl, cycloalkyl, heterocyclyl or heterocyclyl-lower alkyl;
- $R^7$ ,  $R^8$  independently represent hydrogen, aryl, aralkyl, lower alkyl, lower alkenyl, cycloalkyl, heterocyclyl or heterocyclyl-lower alkyl;
- $R^9$ ,  $R^{10}$  independently represent hydrogen, aryl, arylcycloalkyl, aralkyl, lower alkyl, lower alkenyl, lower alkynyl, cycloalkyl, heterocyclyl or heterocyclyl-lower alkyl, in which one, several, or all hydrogen atoms may be replaced by halogen or in which one or two hydrogen atoms may be replaced by hydroxy, nitro, cyano, trifluoromethyl, trifluoromethoxy, -O-lower alkyl, -NH-lower alkyl, -N(lower alkyl)<sub>2</sub>, -S-lower alkyl, -
- 15  
20  
25  
30

COO-lower alkyl, -CONH-lower alkyl, -CON(lower alkyl)<sub>2</sub>, -CO-lower alkyl, -NHCO-lower alkyl, -O-lower alkenyl with 3 to 5 carbon atoms, -NH-lower alkenyl with 3 to 5 carbon atoms, -N(lower alkenyl with 3 to 5 carbon atoms)<sub>2</sub>, -S lower alkenyl with 3 to 5 carbon atoms, -COO-lower alkenyl with 3 to 5 carbon atoms, -CONH-lower alkenyl with 3 to 5 carbon atoms, -CON(lower alkenyl with 3 to 5 carbon atoms)<sub>2</sub>, -CO-lower alkenyl with 3 to 5 carbon atoms, -NHCO-lower alkenyl with 3 to 5 carbon atoms, -O-lower alkynyl with 3 to 5 carbon atoms, -NH-lower alkynyl with 3 to 5 carbon atoms, -N(lower alkynyl with 3 to 5 carbon atoms)<sub>2</sub>, -S-lower alkynyl with 3 to 5 carbon atoms, -COO-lower alkynyl with 3 to 5 carbon atoms, -CONH-lower alkynyl with 3 to 5 carbon atoms, CON(lower alkynyl with 3 to 5 carbon atoms)<sub>2</sub>, -CO-lower alkynyl with 3 to 5 carbon atoms, -NHCO-lower alkynyl with 3 to 5 carbon atoms;

R<sup>11</sup> represents lower alkyl, aryl, aralkyl, heterocyclyl or heterocyclyl-lower alkyl;

R<sup>12</sup> and R<sup>13</sup> independently represent hydrogen, lower alkyl, cycloalkyl, aryl, aralkyl, heterocyclyl or heterocyclyl-lower alkyl;


R<sup>14</sup> represents lower alkyl, aryl, cycloalkyl, heterocyclyl, R<sup>12</sup>R<sup>13</sup>N-, R<sup>11</sup>O-;

-X-Y- independently represents -CH<sub>2</sub>-CH<sub>2</sub>-, -O-CH<sub>2</sub>-, -S-CH<sub>2</sub>-, -SO<sub>2</sub>-CH<sub>2</sub>- and -NR<sup>15</sup>-CO-;

R<sup>15</sup> represents hydrogen, lower alkyl or aralkyl;

and optically pure enantiomers, mixtures of enantiomers such as, for example, racemates, optically pure diastereoisomers, mixtures of diastereoisomers, diastereoisomeric racemates, mixtures of diastereoisomeric racemates, or meso forms and pharmaceutically acceptable salts thereof.

## 2. Compounds of the formula (II)




Formula (II)

wherein:

- 5  $R^1, R^2, R^3, R^4$  independently represent cyano, nitro, halogen, hydrogen, hydroxy, lower alkyl, lower alkenyl, lower alkoxy, lower alkenyloxy, trifluoromethyl, trifluoromethoxy, cycloalkyloxy, aryloxy, aralkyloxy, heterocyclyloxy, heterocyclylalkyloxy,  $R^{11}CO-$ ,  $NR^{12}R^{13}CO-$ ,  $R^{12}R^{13}N-$ ,  $R^{11}OOC-$ ,  $R^{11}SO_2NH-$ , or  $R^{14}CO-NH-$ , or  $R^2$  and  $R^3$  together as well as  $R^1$  and  $R^2$  together and  $R^3$  and  $R^4$  together  
 10 may form with the phenyl ring a five, six or seven-membered saturated ring containing one or two oxygen atoms;  
 $R^5$  independently represents aryl, aralkyl, lower alkyl, lower alkenyl, trifluoromethyl, cycloalkyl, heterocyclyl or heterocyclyl-lower alkyl;  
 $R^6$  independently represents hydrogen, aryl, aralkyl, lower alkyl, lower alkenyl,  
 15 trifluoromethyl, cycloalkyl, heterocyclyl or heterocyclyl-lower alkyl;  
 $R^7, R^8, R^9, R^{10}$  independently represent hydrogen, aryl, aralkyl, lower alkyl, lower alkenyl, cycloalkyl, heterocyclyl or heterocyclyl-lower alkyl;  
 $R^{11}$  represents lower alkyl, aryl, aralkyl, heterocyclyl or heterocyclyl-lower alkyl;  
 $R^{12}$  and  $R^{13}$  independently represent hydrogen, lower alkyl, cycloalkyl, aryl, aralkyl,  
 20 heterocyclyl or heterocyclyl-lower alkyl;  
 $R^{14}$  represents lower alkyl, aryl, cycloalkyl, heterocyclyl,  $R^{12}R^{13}N-$ ,  $R^{11}O-$ ;  
 $-X-Y-$  independently represents  $-CH_2-CH_2-$ ,  $-O-CH_2-$ ,  $-S-CH_2-$ ,  $-SO_2-CH_2-$  and  $-NR^{15}CO-$ ;  
 $R^{15}$  represents hydrogen, lower alkyl or aralkyl;  
 25 and optically pure enantiomers, mixtures of enantiomers such as, for example, racemates, optically pure diastereoisomers, mixtures of diastereoisomers, diastereoisomeric racemates, mixtures of diastereoisomeric racemates, or meso forms and pharmaceutically acceptable salts thereof.

## 3. Compounds of the formula (III)



Formula (III)

10 wherein:

R'<sup>1</sup> and R'<sup>2</sup> independently represent hydrogen, hydroxy, lower alkoxy, lower alkenyloxy or halogen or may form with the phenyl ring a five, six or seven membered-ring containing one or two oxygen atoms;

15 R'<sup>3</sup> represents aryl, aralkyl, lower alkyl, lower alkenyl, cycloalkyl, heterocyclyl or heterocyclyl-lower alkyl;

R'<sup>4</sup>, R'<sup>5</sup> independently represent hydrogen, aryl, aralkyl, lower alkyl, lower alkenyl, cycloalkyl, heterocyclyl or heterocyclyl-lower alkyl;

-X-Y- independently represents -CH<sub>2</sub>-CH<sub>2</sub>-, -O-CH<sub>2</sub>-, -S-CH<sub>2</sub>-, -SO<sub>2</sub>-CH<sub>2</sub>- and -NR'<sup>6</sup>-

20 CO-;

R'<sup>6</sup> represents hydrogen, lower alkyl or aralkyl;

and optically pure enantiomers, mixtures of enantiomers such as, for example, racemates, optically pure diastereoisomers, mixtures of diastereoisomers, diastereoisomeric racemates, mixture of diastereoisomeric racemates, or meso forms

25 and pharmaceutically acceptable salts thereof.

4. A compound according to any of claims 1 to 3, selected from the group consisting of

2-[1-(3,4-Dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-  
5 *N*-naphthalen-1-ylmethyl-acetamide;

*N*-Benzo[1,3]dioxol-5-ylmethyl-2-[1-(3,4-dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-acetamide;

10 2-[1-(3,4-Dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-  
*N*-indan-2-yl-acetamide;

2-[5-(3,4-Dimethoxy-benzyl)-7,8-dimethoxy-2,3-dihydro-5H-benzo[f][1,4]oxazepin-4-yl]-  
15 *N*-indan-2-yl-acetamide;

2-[5-(3,4-Dimethoxy-benzyl)-7,8-dimethoxy-2,3-dihydro-5H-benzo[f][1,4]oxazepin-4-yl]-  
*N*-indan-1-yl-acetamide;

2-[1-(3,4-Dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-  
20 *N*-indan-1-yl-acetamide;

2-[9-(3,4-Dimethoxy-benzyl)-2,3-dimethoxy-5,5-dioxo-5,6,7,9-tetrahydro-5 $\lambda$ -thia-8-  
aza-benzocyclohepten-8-yl]-*N*-indan-2-yl-acetamide;

25 2-[9-(3,4-Dimethoxy-benzyl)-2,3-dimethoxy-5,5-dioxo-5,6,7,9-tetrahydro-5 $\lambda$ -thia-8-  
aza-benzocyclohepten-8-yl]-*N*-indan-1-yl-acetamide;

2-[1-(3,4-Dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-  
*N*-indan-1-yl-acetamide;

30

2-[1-(3,4-Dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-  
*N*-indan-2-yl-2-phenyl-acetamide;

2-[9-(3,4-Dimethoxy-benzyl)-2,3-dimethoxy-6,7-dihydro-9H-5-thia-8-aza-  
5 benzocyclohepten-8-yl]-*N*-naphthalen-1-ylmethyl-acetamide;

2-[9-(3,4-Dimethoxy-benzyl)-2,3-dimethoxy-6,7-dihydro-9H-5-thia-8-aza-  
benzocyclohepten-8-yl]-*N*-(2-ethoxy-benzyl)-acetamide;

10 2-[9-(3,4-Dimethoxy-benzyl)-2,3-dimethoxy-6,7-dihydro-9H-5-thia-8-aza-  
benzocyclohepten-8-yl]-*N*-indan-1-yl-acetamide;

2-[5-(3,4-Dimethoxy-benzyl)-7,8-dimethoxy-2,3-dihydro-5H-benzo[f][1,4]oxazepin-4-  
yl]-*N*-(1,2,3,4-tetrahydro-naphthalen-1-yl)-acetamide;

15 *N*-Benzyl-2-[9-(3,4-dimethoxy-benzyl)-2,3-dimethoxy-6,7-dihydro-9H-5-thia-8-aza-  
benzocyclohepten-8-yl]-acetamide;

2-[5-(3,4-Dimethoxy-benzyl)-7,8-dimethoxy-2,3-dihydro-5H-benzo[f][1,4]oxazepin-4-  
20 yl]-*N*-indan-1-yl-acetamide;

*N*-Butyl-2-[1-(3,4-dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-  
benzo[c]azepin-2-yl]-2-phenyl-acetamide;

25 2-[1-(3,4-Dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-  
*N*-indan-1-yl-2-phenyl-acetamide;

*N*-Benzo[1,3]dioxol-5-ylmethyl-2-[1-(3,4-dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-  
tetrahydro-benzo[c]azepin-2-yl]-2-phenyl-acetamide;

30

*N*-Cyclopentyl-2-[1-(3,4-dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-2-phenyl-acetamide;

2-[1-(3,4-Dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-  
5 *N*-furan-2-ylmethyl-2-phenyl-acetamide;

{2-[1-(3,4-Dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-  
2-phenyl-acetylamino}-acetic acid ethyl ester;

10 2-[1-(3,4-Dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-  
2-phenyl-*N*-pyridin-4-ylmethyl-acetamide;

2-[1-(3,4-Dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-  
2-phenyl-*N*-pyridin-3-ylmethyl-acetamide;

15 *N*-Cyclopropyl-2-[1-(3,4-dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-  
benzo[c]azepin-2-yl]-2-phenyl-acetamide;

2-[1-(3,4-Dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-  
20 *N*-(2-oxo-tetrahydro-furan-3-yl)-2-phenyl-acetamide;

2-[1-(3,4-Dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-  
*N*-(4-methoxy-indan-1-yl)-acetamide;

25 2-[1-(3,4-Dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-  
*N*-(3-phenyl-indan-1-yl)-acetamide;

2-[1-(3,4-Dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-  
*N*-(4-methyl-indan-1-yl)-acetamide;

30

2-{2-[1-(3,4-Dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-2-phenyl-acetylamino}-3-hydroxy-propionic acid methyl ester;

2-[1-(3,4-Dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-  
5 *N*-ethylcarbamoylmethyl-2-phenyl-acetamide;

2-[1-(3,4-Dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-  
*N*-[(ethyl-methyl-carbamoyl)-methyl]-2-phenyl-acetamide;

10 2-[1-(3,4-Dimethoxy-benzyl)-8-hydroxy-7-methoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-*N*-indan-1-yl-acetamide;

2-[8-Benzyloxy-1-(3,4-dimethoxy-benzyl)-7-methoxy-1,3,4,5-tetrahydro-  
benzo[c]azepin-2-yl]-*N*-indan-1-yl-acetamide;

15

3-{2-[1-(3,4-Dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-2-phenyl-acetylamino}-propionic acid methyl ester;

*N*-Benzo[1,3]dioxol-5-ylmethyl-2-[1-(3,4-dimethoxy-benzyl)-8-hydroxy-7-methoxy-  
20 1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-2-phenyl-acetamide;

*N*-(1*H*-Benzoimidazol-2-ylmethyl)-2-[1-(3,4-dimethoxy-benzyl)-7,8-dimethoxy-  
1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-2-phenyl-acetamide;

25 3-{2-[1-(3,4-Dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-2-phenyl-acetylamino}-*N,N*-dimethyl-propionamide;

3-{2-[1-(3,4-Dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-2-phenyl-acetylamino}-*N*-ethyl-*N*-methyl-propionamide;

30



2-[1-(3,4-Dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-  
*N*-(1-methyl-1H-indol-3-ylmethyl)-2-phenyl-acetamide;

2-[1-(3,4-Dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-  
5 *N*-isoxazol-5-ylmethyl-2-phenyl-acetamide;

2-[1-(3,4-Dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-  
*N*-(1H-indol-3-ylmethyl)-2-phenyl-acetamide;

10 2-[1-(3,4-Dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-  
*N*-(1-methyl-1H-benzoimidazol-2-ylmethyl)-2-phenyl-acetamide;

2-[1-(3,4-Dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-  
*N*-isoquinolin-1-ylmethyl-2-phenyl-acetamide;

15 2-[1-(3,4-Dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-  
2-phenyl-*N*-(4-[1,2,3]thiadiazol-4-yl-benzyl)-acetamide;

2-[1-(3,4-Dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-  
20 *N*-(1-methyl-1H-indazol-3-ylmethyl)-2-phenyl-acetamide;

*N*-Cyanomethyl-2-[1-(3,4-dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-  
benzo[c]azepin-2-yl]-2-phenyl-acetamide;

25 *N*-(2-Acetylamino-ethyl)-2-[1-(3,4-dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-  
tetrahydro-benzo[c]azepin-2-yl]-2-phenyl-acetamide;

2-[1-(3,4-Dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-  
2-phenyl-*N*-(2,2,2-trifluoro-ethyl)-acetamide;

2-[1-(3,4-Dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-  
*N*-(2-methylsulfanyl-ethyl)-2-phenyl-acetamide;

2-[1-(3,4-Dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-  
5 2-phenyl-*N*-quinolin-2-ylmethyl-acetamide;

*N*-(2-Cyano-ethyl)-2-[1-(3,4-dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-  
benzo[c]azepin-2-yl]-2-phenyl-acetamide;

10 2-[1-(3,4-Dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-  
*N*-(3-methoxy-propyl)-2-phenyl-acetamide;

2-[1-(3,4-Dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-  
*N*-(3-ethoxy-propyl)-2-phenyl-acetamide;

15 2-[1-(3,4-Dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-  
2-phenyl-acetamide;

2-[1-(3,4-Dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-  
20 2-phenyl-*N*-pyrazin-2-ylmethyl-acetamide;

2-[1-(3,4-Dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-  
2-phenyl-*N*-prop-2-ynyl-acetamide;

25 *N*-tert-Butyl-2-[1-(3,4-dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-  
benzo[c]azepin-2-yl]-2-phenyl-acetamide;

2-[1-(3,4-Dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-  
*N*-(3-methyl-butyl)-2-phenyl-acetamide;

30

2-[1-(3,4-Dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-  
*N*-(3,3-dimethyl-butyl)-2-phenyl-acetamide;

2-[1-(3,4-Dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-  
5 *N*-(1-ethyl-propyl)-2-phenyl-acetamide;

2-[1-(3,4-Dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-  
*N*-(2-ethylsulfanyl-ethyl)-2-phenyl-acetamide;

10 2-[1-(3,4-Dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-  
*N*-(2-hydroxy-ethyl)-2-phenyl-acetamide;

2-[1-(3,4-Dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-  
*N*-(3-hydroxy-propyl)-2-phenyl-acetamide;

15 [1-(3,4-Dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-  
phenyl-acetic acid *N,N*-dimethyl-hydrazide;

2-[8-Allyloxy-1-(3,4-dimethoxy-benzyl)-7-methoxy-1,3,4,5-tetrahydro-benzo[c]azepin-  
20 2-yl]-*N*-indan-1-yl-acetamide;

2-[1-(3,4-Dimethoxy-benzyl)-7-methoxy-8-propoxy-1,3,4,5-tetrahydro-benzo[c]azepin-  
2-yl]-*N*-indan-1-yl-acetamide;

25 2-[1-(3,4-Dimethoxy-benzyl)-8-isopropoxy-7-methoxy-1,3,4,5-tetrahydro-  
benzo[c]azepin-2-yl]-*N*-indan-1-yl-acetamide;

2-[8-(2,2-Difluoro-ethoxy)-1-(3,4-dimethoxy-benzyl)-7-methoxy-1,3,4,5-tetrahydro-  
benzo[c]azepin-2-yl]-*N*-indan-1-yl-acetamide;

30 *N*-Benzo[1,3]dioxol-5-ylmethyl-2-[8-(2,2-difluoro-ethoxy)-1-(3,4-dimethoxy-benzyl)-  
7-methoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-2-phenyl-acetamide;

*N*-Benzo[1,3]dioxol-5-ylmethyl-2-[1-(3,4-dimethoxy-benzyl)-8-isopropoxy-7-methoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-2-phenyl-acetamide;

5 2-[5-(3,4-Dichloro-benzyl)-7,8-dimethoxy-2-oxo-1,2,3,5-tetrahydro-benzo[e][1,4]diazepin-4-yl]-*N*-indan-1-yl-acetamide;

2-[1-(*S*)-(3,4-Dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-*N*-indan-1-yl-acetamide;

10

2-[1-(*S*)-(3,4-Dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-*N*-indan-2-yl-acetamide

5. A compound according to any of claims 1 to 4, selected from the group consisting  
15 of

2-[1-(3,4-Dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-*N*-indan-2-yl-acetamide;

20 2-[5-(3,4-Dimethoxy-benzyl)-7,8-dimethoxy-2,3-dihydro-5H-benzo[f][1,4]oxazepin-4-yl]-*N*-indan-1-yl-acetamide;

2-[1-(3,4-Dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-*N*-indan-1-yl-acetamide;

25

2-[1-(3,4-Dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-*N*-indan-1-yl-acetamide;

2-[1-(3,4-Dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-  
30 *N*-indan-2-yl-2-phenyl-acetamide;

*N*-Butyl-2-[1-(3,4-dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-2-phenyl-acetamide;

2-[1-(3,4-Dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-  
5 *N*-indan-1-yl-2-phenyl-acetamide;

*N*-Benzo[1,3]dioxol-5-ylmethyl-2-[1-(3,4-dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-2-phenyl-acetamide;

10 *N*-Cyclopentyl-2-[1-(3,4-dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-2-phenyl-acetamide;

2-[1-(3,4-Dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-  
*N*-furan-2-ylmethyl-2-phenyl-acetamide;

15 {2-[1-(3,4-Dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-2-phenyl-acetylamino}-acetic acid ethyl ester;

2-[1-(3,4-Dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-  
20 2-phenyl-*N*-pyridin-3-ylmethyl-acetamide;

3-{2-[1-(3,4-Dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-2-phenyl-acetylamino}-propionic acid methyl ester;

25 *N*-(1H-Benzoimidazol-2-ylmethyl)-2-[1-(3,4-dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-2-phenyl-acetamide;

2-[1-(3,4-Dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-  
*N*-(1-methyl-1H-indol-3-ylmethyl)-2-phenyl-acetamide;

30

2-[1-(3,4-Dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-  
*N*-isoxazol-5-ylmethyl-2-phenyl-acetamide;

2-[1-(3,4-Dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-  
5 *N*-(1H-indol-3-ylmethyl)-2-phenyl-acetamide;

2-[1-(3,4-Dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-  
*N*-isoquinolin-1-ylmethyl-2-phenyl-acetamide;

10 2-[1-(3,4-Dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-  
2-phenyl-*N*-(4-[1,2,3]thiadiazol-4-yl-benzyl)-acetamide;

2-[1-(3,4-Dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-  
*N*-(1-methyl-1H-indazol-3-ylmethyl)-2-phenyl-acetamide;

15 *N*-Cyanomethyl-2-[1-(3,4-dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-  
benzo[c]azepin-2-yl]-2-phenyl-acetamide;

2-[1-(3,4-Dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-  
20 2-phenyl-*N*-(2,2,2-trifluoro-ethyl)-acetamide;

2-[1-(3,4-Dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-  
*N*-(2-methylsulfanyl-ethyl)-2-phenyl-acetamide;

25 2-[1-(3,4-Dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-  
2-phenyl-*N*-quinolin-2-ylmethyl-acetamide;

*N*-(2-Cyano-ethyl)-2-[1-(3,4-dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-  
benzo[c]azepin-2-yl]-2-phenyl-acetamide;

30

2-[1-(3,4-Dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-  
*N*-(3-methoxy-propyl)-2-phenyl-acetamide;

2-[1-(3,4-Dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-  
5 *N*-(3-ethoxy-propyl)-2-phenyl-acetamide;

2-[1-(3,4-Dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-  
2-phenyl-*N*-pyrazin-2-ylmethyl-acetamide;

10 2-[1-(3,4-Dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-  
2-phenyl-*N*-prop-2-ynyl-acetamide;

2-[1-(3,4-Dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-  
*N*-(3-methyl-butyl)-2-phenyl-acetamide;

15 2-[1-(3,4-Dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-  
*N*-(3,3-dimethyl-butyl)-2-phenyl-acetamide;

2-[1-(3,4-Dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-  
20 *N*-(1-ethyl-propyl)-2-phenyl-acetamide;

2-[1-(3,4-Dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-  
*N*-(2-ethylsulfanyl-ethyl)-2-phenyl-acetamide;

25 2-[1-(3,4-Dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-  
*N*-(2-hydroxy-ethyl)-2-phenyl-acetamide;

2-[8-Allyloxy-1-(3,4-dimethoxy-benzyl)-7-methoxy-1,3,4,5-tetrahydro-benzo[c]azepin-  
2-yl]-*N*-indan-1-yl-acetamide;

30

2-[1-(3,4-Dimethoxy-benzyl)-7-methoxy-8-propoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-*N*-indan-1-yl-acetamide;

5 2-[1-(3,4-Dimethoxy-benzyl)-8-isopropoxy-7-methoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-*N*-indan-1-yl-acetamide;

2-[8-(2,2-Difluoro-ethoxy)-1-(3,4-dimethoxy-benzyl)-7-methoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-*N*-indan-1-yl-acetamide;

10 *N*-Benzo[1,3]dioxol-5-ylmethyl-2-[8-(2,2-difluoro-ethoxy)-1-(3,4-dimethoxy-benzyl)-7-methoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-2-phenyl-acetamide;

*N*-Benzo[1,3]dioxol-5-ylmethyl-2-[1-(3,4-dimethoxy-benzyl)-8-isopropoxy-7-methoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-2-phenyl-acetamide;

15

2-[1-(*S*)-(3,4-Dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-*N*-indan-1-yl-acetamide;

20 2-[1-(*S*)-(3,4-Dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-*N*-indan-2-yl-acetamide;

6. Pharmaceutical compositions for the treatment of disorders which are associated with the role of orexin, especially disorders such as obesity and sleep disorders, containing one or more compounds of any one of claims 1 to 5, or a pharmaceutically acceptable salt thereof, and usual carrier materials and adjuvants.

25

7. The compounds of any one of claims 1 to 5, or a pharmaceutically acceptable salt thereof, for use as medicaments for the treatment of disorders which are associated with a role of orexin, especially obesity and sleep disorders.

30

8. A method of treating or preventing diseases or disorders where an antagonist of a human orexin receptor is required, which comprises administering to a subject in



need thereof an effective amount of a compound as claimed in any one of claims 1 to 5, or a pharmaceutically acceptable salt thereof.

- 5 9. A process for the manufacture of pharmaceutical compositions for the treatment of disorders associated with the role of orexin, especially obesity and sleep disorders, containing one or more compounds as claimed in any one of claims 1 to 5, or a pharmaceutically acceptable salt or salts thereof, as active ingredients which process comprises mixing one or more active ingredient or ingredients with pharmaceutically acceptable excipients and adjuvants in a manner known per se.

10

10. The novel compounds, processes and methods as well as the use of such compounds substantially as described herein before.

15

20

25

30